Main Line pharma company reports 'exciting step forward' with experimental autism treatment

Zynerba Pharmaceuticals Inc., a developer of synthetic cannabinoid therapies, posted positive study results Wednesday from mid-stage testing of its experimental autism spectrum disorder treatment. The Devon company's stock, which closed Tuesday at $6.19 per share, was up 15% at one point in premarket trading before settling back to $6.32 per share when the market opened. The increase came after Zynerba (NASDAQ: ZYNE) released the positive results of a phase-II study testing its lead new dr ug candidate…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news